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The transcription factor AP-1 plays a central role in the transcrip-
tional regulation of specific types of high-risk human papilloma-
viruses (HPVs) such as HPV16 and HPV18, which are etiologically
associated with the development of cancer of the uterine cervix in
women. In our study, we investigated the AP-1 binding activity
and the expression pattern of different members of the AP-1
transcription factor family (c-Jun, JunB, JunD, c-Fos, FosB, Fra-1
and Fra-2) in different grades of cervical lesions starting from
mild dysplasia to invasive cervical tumors, including normal con-
trol tissues, using specific antibodies raised against each of the
AP-1 members. Results indicate that though AP-1 showed high
binding activity and the majority of its members were highly
expressed in tumor tissues, there is a distinct pattern of gradual
increase of c-fos and a concomitant decrease of fra-1 expression
that perfectly match the progression of cervical lesions. While
c-fos is highly expressed in invasive cervical tumor, the expression
of fra-1 becomes almost nil or absent, but the reverse is true in
both controls and early precancerous lesions. These findings cor-
roborate the results obtained in the cervical cancer cell line, HeLa.
Interestingly, despite very low or absent AP-1 binding in normal
as well as in premalignant lesions, AP-1 transcription and its
binding activity was found to be very high in malignant tissues
showing a preferential heterodimerization of c-fos with JunB in-
stead of its canonical dimerization partner c-jun. Both in vivo and
in vitro studies demonstrate that the overexpression of c-fos and
downregulation of fra-1 expression as well as a change in the
dimerization pattern of the AP-1 complex seem to play a crucial
role during progression to malignancy. In a previous study, we
demonstrated that a synthetic antioxidant, pyrrolidine dithiocar-
bamate (PDTC) can selectively downregulate HPV expression in
human keratinocytes and cervical cancer cell lines. Since a redox
regulatory pathway is involved in the expression of HPV that can
be modulated by an antioxidant-induced reconstitution of the
AP-1 transcription complex, we have used curcumin (diferuloyl-
methane), an active component of the perennial herb turmeric,
which is a potent antioxidant and is well-known for its antiinflam-
matory and anticarcinogenic activity, to modulate the transcrip-
tion of AP-1 and HPV. We demonstrate for the first time that
curcumin can selectively downregulate HPV18 transcription as
well as the AP-1 binding activity in HeLa cells. Most interestingly,
curcumin can reverse the expression dynamics of c-fos and fra-1 in
this tumorigenic cell line, mimicking the expression pattern ob-
served in normal controls or precancerous lesions. Observation of
curcumin-mediated complete downregulation of AP-1 binding ac-
tivity and reversal of c-fos/fra-1 transcription to a normal state in
tumorigenic HeLa cells represents a novel mechanism that can
control transcription of pathogenic HPVs during keratinocyte
differentiation and progression of cervical cancer. Our study thus
provides a basis for developing a novel therapeutic approach to
control pathogenic HPV infection by using potent antioxidative
agents, such as curcumin.
© 2004 Wiley-Liss, Inc.
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Cervical cancer is caused by infection of specific types of
high-risk human papillomaviruses (HPVs), such as HPV types 16
and 18 (HPV16 and HPV18).1–3 In India, cancer of the uterine
cervix is the major cancer harboring HPV (in almost 98%), and
more than 90% of patients with this cancer are specifically infected
with HPV16.4,5 Constitutive expression of 2 early genes, E6 and
E7, of high-risk HPVs responsible for tumorigenic transformation6
is mainly dependent on the availability of host-cell transcription
factor, activator protein-1 (AP-1). AP-1 plays a key role during
development of cervical cancer,7 because site-directed mutagene-
sis of the corresponding AP-1 binding sites within the viral up-
stream regulatory regions (URR) almost completely abolishes
transcription of URR-driven reporter constructs, either under tran-
sient transfection conditions8,9 or in stable differentiation-depen-
dent infection assays in organotypic “raft” cultures.10,11
The AP-1 transcription factor that plays a crucial role in the
transcriptional regulation of almost all HPV types investigated so
far,8 is formed by either homodimerization of 2 jun proteins (c-jun,
JunB, JunD) or heterodimerization of Jun and fos proteins (c-fos,
FosB, Fra-1 and Fra-2)12–14 through the “leucine zipper.”13 The
binding site for AP-1 was recognized as the TPA (12-O-tetrade-
canoyl phorbol 13-acetate) response element (TRE) of several
cellular and viral genes, including MTIIa, IL-1, SV-40 and poly-
oma.15,16 In vitro studies have also shown that Jun/Fos het-
erodimers are more efficient DNA binding proteins than Jun/Jun
homodimers.13 Since DNA binding is a necessary prerequisite of
transactivation, the expression of different proteins of the Jun and
Fos family is crucial for the activation of downstream genes
regulated by AP-1. In a previous study, we demonstrated a higher
binding activity of AP-1 in both HPV-positive and HPV-negative
cervical carcinoma cell lines, namely HeLa and C33a, respec-
tively, as well as in HPV16-positive human keratinocyte HPK1a
cells.
Since AP-1 is indispensable for efficient epithelial tissue–spe-
cific gene expression of HPV8 and it is also regulated during
keratinocytes differentiation,17 we investigated the binding activity
of AP-1 in in vivo tissue biopsies from different grades of cervical
lesions (low grade squamous intraepithelial lesions [LSIL] and
high grade squamous intraepithelial lesions [HSIL]), including
invasive cancer and normal controls. We show for the first time
that the DNA binding affinity of AP-1, as well as the expression of
its constituent members, vary as a function of the severity of
cervical lesions. We also demonstrate that it is not the c-jun but
mainly the junB that heterodimerizes with c-fos to form the func-
tional AP-1 complex during progression.
In addition, we investigated the transcriptional regulatory role of
a potential antioxidative agent curcumin (diferuloylmethane), an
active component of the perennial herb turmeric, which is exten-
sively used for imparting specific flavor and yellow color to curry
and exhibits antiinflammatory and antitumor activity.18,19 In a
previous study, we had demonstrated that the transactivation and
DNA binding affinity of AP-1 can be modulated by alterations of
the intracellular redox status if the cells are treated with a potent
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antioxidative agent, pyrrolidine dithiocarbamate (PDTC),7 which
can block not only the transcription of endogenous cellular NF-
kB–responsive genes such as the monocyte chemoattractant pro-
tein 1 (MCP-1) gene,20 but also selectively suppressed HPV16
expression. Although PDTC induced elevated binding of the AP-1
transcription factor to its cognate recognition sites within the viral
regulatory region, it was revealed that the blockage of HPV tran-
scription was mainly due to antioxidant-induced reconstitution of
the AP-1 transcription complex.7
Curcumin, which exhibits antiinflammatory and antitumor ac-
tivity,19,20 has been shown to suppress activation of transcription
factor NF-kB.21 It has also been shown to inhibit human immu-
nodeficiency virus 1 long terminal repeat (HIV 1 LTR)-directed
gene expression and viral replication,22 but the mechanism(s) of
these effects is not yet clearly understood.
In our study, we investigated the effects of curcumin in the
HPV18-positive cervical carcinoma cell line HeLa and demon-
strate that curcumin is not only a potent inhibitor of AP-1, it
selectively suppresses HPV transcription in cervical cancer cells.
This antioxidant-induced abolition of HPV oncogene expression,
coupled with the downregulation of AP-1 binding activity, repre-
sents a novel mechanism that can control pathogenic HPV expres-
sion during keratinocyte differentiation and progression of cervical
cancer.
Material and methods
Tissue specimens
We collected 100 different grades of cervical tissue specimens
comprising 50 invasive cancers, 25 each of LSIL and HSIL. A
total of 30 normal cervical tissue samples were obtained from the
patients undergoing surgery for gynecological problems other than
cervical cancer. The tissue samples from women diagnosed to be
at different grades were obtained from the patients attending the
cancer clinics of Lok Nayak Hospital, Maulana Azad Medical
College, New Delhi. Each biopsy specimen was bisected and
one-half was subjected to histopathologic examination and the
other one-half was immediately frozen in liquid nitrogen for mo-
lecular investigation. Only histopathologically proven samples
were considered for the study. Informed consent was obtained
from each patient before obtaining the biopsy specimens.
Cell culture
The HPV18-positive cervical carcinoma cell line HeLa was
maintained in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% heat-inactivated fetal calf serum and 1%
penicillin/streptomycin. Curcumin was obtained from Sigma
Chemicals (St. Louis, MO) and was freshly dissolved in ethanol
and diluted in the medium immediately before use.
DNA extraction and PCR detection of HPV
High molecular-weight genomic DNA was isolated from nor-
mal, premalignant and tumor tissue specimens by standard pro-
teinase K digestion and a phenol-chloroform extraction proce-
dure.5,23 Southern blot hybridization as well as PCR for detection
for HPV16 DNA and HPV18 DNA were carried out as described
previously,5,23 using type-specific probes and oligonucleotide
primers (HPV16 (1), 5-AAG GCC AAC TAA ATG TCA C-3;
HPV16 (2), 5-CTG CTT TTA TAC TAA CCG G-3; HPV18 (1),
5-ACC TTA ATG AAA AAC CAC GA-3; HPV18 (2), 5-CGT
CGT TTA GAG TCG TTC CTG-3). Initially, all DNA samples
were tested for the presence of any HPV type by using a pair of
consensus primers located within the conserved L1 open reading
frame (ORF) of the HPV genome (MY 11, 5-GCM CAG GGW
CAT AAY AAT GC-3; MY 09, 5-CGT CCM ARR GGA WAC
TGA TC-3; where M  AC, W  AT, Y  CT, R 
AG). PCR was performed in a 25 l reaction mix containing 100
ng DNA, 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2,
125 M of each dNTP (dATP, dCTP, dGTP and dTTP), 5 pmol of
each oligonucleotide primer and 0.5 U Taq DNA polymerase
(Perkin-Elmer Biosystems, Foster City, CA, USA). The tempera-
ture profile used for amplification constituted an initial denatur-
ation at 95°C for 5 min followed by 35 cycles with denaturation at
95°C for 30 sec, annealing at 55°C for 30 sec and extension at
72°C for 1 min, which was extended for 4 min in the final cycle.
The oligonucleotide primers were synthesized in an automated
Applied Biosystems DNA synthesizer (Model 381A; Applied Bio-
systems, Foster City, CA, USA) using the phosphoramidite
method and purified in high pressure liquid chromatography
(HPLC).
Extraction of RNA and Northern blotting
Cellular RNA from cervical tissue biopsies as well as from cell
cultures was extracted from snap frozen biopsies in liquid nitrogen
by the single-step acid guanidium thiocyanate phenol-chloroform
extraction method24 and also by using TRI Reagent (Sigma Chem-
icals) according to the manufacturer’s protocol. The quality and
quantity of RNA was estimated by electrophoresis of 2 l of RNA
solution on an ethidium bromide–stained 1% agarose gel in 3-[N-
morpholino]propane-sulfonic acid (MOPS) buffer. Presence of at
least 2 bands corresponding to 28S and 18S RNA was a good
indication of high-quality RNA. Concentration of RNA was also
estimated by a dual beam ultraviolet (UV) spectrophotometer at a
wavelength of 260 nanometers. Northern blotting was carried out
using standard protocols.7
Preparation of nuclear extract
Nuclear extracts were prepared by the method of Riol et al.,25
with certain modifications. Frozen tissues were minced and resus-
pended in ice-cold hypotonic buffer (20 mM HEPES [pH 7.6],
20% [vol/vol] glycerol, 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 1 mM DTT, 0.1% Triton X-100, 100 mM phenyl methyl
sulfonyl fluoride (PMSF), 2 g/ml leupeptin and 10 g/ml A-
proteinin). After 15 min incubation on ice, lysates were centri-
fuged at 850g for 15 min at 4°C in a microcentrifuge. The super-
natant was transferred to a new tube and designated as the
cytoplasmic extract. The pellet was washed once with hypotonic
buffer and extracted on ice with 2.5 times the pellet size of nuclear
extraction buffer (20 mM HEPES [pH 7.6], 25% [vol/vol] glyc-
erol, 500 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT,
0.1% Triton X-100, 100 mM PMSF, 2 g/ml leupeptin and 10
g/ml A-proteinin). After 1 hr, the extraction mixture was centri-
fuged at 18,000g at 4°C in a microcentrifuge for 15 min. The
resulting supernatant was designated as the nuclear extract. The
protein concentration of the extracts was determined by the spec-
trophotometric method and the extract was stored at –70 °C in a
deep freezer or in liquid nitrogen until use. Nuclear extract from
cultured HeLa cells were also prepared by this method.
Electrophoretic mobility shift assay
For electrophoretic mobility shift assay (EMSA), the following
oligonucleotides were used: an AP-1 consensus sequence 5-
CGCTTGATGACTCAGCCGGAA-3 (consensus binding sites are
underlined and italicized), an Oct-1 consensus oligonucleotide
5-TGTCGAATGCAAATCACTAGAA-3 and a Sp-1 consensus
sequence 5-ATTCGATCGGGGCGGGGCGAG-3. The oligonu-
cleotide primers were synthesized in an Applied Biosystems DNA
synthesizer using phosphoramidite chemistry. The above oligonu-
cleotides were annealed and labeled with [-32P] ATP (3,000
Ci/mmol; Jonaki, Hyderabad, India) by T4 polynucleotide kinase
and gel purified in a 15% polyacrylamide gel.7
The binding reaction was performed in a 25 l reaction volume
containing 50% glycerol, 60 mM HEPES (pH 7.9), 20 mM Tris-
HCl (pH 7.9), 300 mM KCl, 5 mM EDTA, 5 mM DTT, 100 g of
BSA per milliliter, 2.5 g of poly (dI-dC) and 10 g of nuclear
extract. After 5 min, 10,000 cpm of the [-32P] ATP 5-end labeled
double-stranded oligonucleotide probe was added and the incuba-
tion was continued for additional 25 min at room temperature. For
monitoring AP-1 composition in supershift assays, 2 g of poly-
clonal antibodies (Abs) directed against the Jun/fos family mem-
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bers (Santa Cruz Biotechnology Inc., Santa Cruz, CA) were added
and the reaction mixture was further incubated for 1 hr at 4°C. The
following Abs were used: c-Jun Ab (epitope corresponding to
aminoterminal domain of mouse c-Jun p39); JunB Ab (epitope
corresponding to carboxy terminal domain of mouse JunB); JunD
Ab (epitope corresponding to carboxy terminus of mouse JunD);
c-fos Ab (epitope corresponding to a highly conserved domain of
c-fos p62 of human origin); FosB Ab (epitope corresponding to
amino acids within the central domain of the FosB protein of
mouse origin); Fra-1 Ab (epitope corresponding to amino terminus
of Fra-1 of rat origin) and Fra-2 (epitope corresponding to carboxy
terminus of Fra-2 of human origin). The DNA-protein complexes
were resolved on 4.5% nondenaturing polyacrylamide gel (cross-
linking ratio, 29:1), dried and exposed overnight to Kodak X-Omat
Films (Kodak India Ltd., India).
Western blotting
Nuclear extracts used for band-shift analysis (30 g of protein
per lane) were separated in 10% polyacrylamide gel, electrotrans-
ferred to Immobilon-P membranes (Millipore Corporation, Bed-
ford, MA), and probed with polyclonal rabbit antibodies of the
corresponding family members (see Electrophoretic mobility shift
assay). The incubation was carried out overnight in PBS supple-
mented with 5% skim milk powder, 0.05% Tween 20 (Sigma), and
different dilutions of respective Abs. The bands were visualized
with an anti-rabbit immunoglobulin G (IgG) antibody conjugated
with horseradish peroxidase, using the Luminol reagent detection
kit (Santa Cruz Biotechnology).
DNA hybridization probes
pHPV 16 and pHPV 18 represent unit-length HPV16 DNA1 and
HPV18 DNA2 cloned in pBR322. pHF-A1,26 harboring an approx-
imately full-length insert of the fibroblast -actin gene, was a
generous gift from L. Kedes (Medical Center, Palo Alto, CA,
USA). The c-DNA for c-fos27 and WAF gene28 were kindly pro-
vided by P. Angel (Deutsches Krebsforschungszentrum, Heidel-
berg, Germany) and B. Vogelstein (John Hopkins University,
Baltimore, MD, USA). The DNA harboring the human homolog
for the fra-1 gene29 was a generous gift from M. Seiki (Cancer
Research Institute, Kanagawa, Japan). All probes were labeled by
the random-priming method.30
Results
All the cervical specimens (n  130), including normal cervical
tissues, were employed for HPV detection by PCR; first by L1
consensus primer, which revealed a total HPV positivity of 10, 49
and 98% in normal, premalignant and malignant cervical tissues,
respectively. A total of 46% of the premalignant lesions (LSIL
32%; HSIL 60%) and as high as 94% of the cancer cases were
positive for high-risk HPV16 and/or HPV18. The binding activity
of AP-1 and the expression profile of its all members, e.g., c-jun,
junB, junD, c-fos, fosB, fra-1 and fra-2, were analyzed in all
spectra of cervical lesions comprising premalignant (LSIL and
HSIL), malignant and normal control tissues. The results showed
a gradual increase in the binding activity and expression of AP-1
and its members with the increasing severity of the cervical le-
sions.
Increased DNA binding activity and expression of AP-1
components changes as a function of severity of cervical lesions
For analysis of the expression and DNA binding activity of the
AP-1 family of transcription factors during the progression of
cervical cancer, we first performed band-shift assays with the
nuclear extracts from tissue biopsy specimens collected from cer-
vical cancer with 32P-labeled probe harboring an AP-1 consensus
sequence. The binding was found to be specific, since the retarded
complex disappeared after competition with a 100-fold molar
excess of a homologous (AP-1), but not with a heterologous, cold
probe containing the consensus sequence for the transcription
factor Oct-1 (Fig. 1). We then used nuclear extracts from normal
and different grades of cervical tissues (LSIL and HSIL) including
invasive cervical cancer biopsies and, interestingly, we recorded a
FIGURE 1 – EMSA using nuclear extracts from invasive cervical
cancer tissues, with a 32P-labeled oligonucleotide harboring an AP-1
consensus sequence. Binding specificity was evidenced by preincuba-
tion with a 100-fold molar addition of the homologous unlabeled
oligonucleotide (Lane b) in comparison with competition experiments
using a heterologous consensus sequence of the Oct-1 transcription
factor (Lane c). The positions of the specific retarded bands are
indicated. The squares mark the unspecific complexes.
FIGURE 2 – Gel shift analysis using nuclear extracts from different
grades of HPV-positive (a) and HPV-negative (b) cervical biopsy
tissues with 32P-labeled oligonucleotide probe harboring an AP-1
consensus sequence. Increasing AP-1 binding activity was observed as
the severity of cervical lesions progressed from normal to invasive
cancer (Lanes a–d) in both (a) and (b). Lane a, normal controls (N);
Lane b, low-grade squamous intraepithelial lesions (LSIL); Lane c,
high-grade squamous intraepithelial lesions (HSIL); Lane d, invasive
cancer (C). The positions of the specific retarded bands are indicated.
The squares mark the unspecific complexes.
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gradual increase in the binding activity of AP-1 (Fig. 2a and b) as
the lesion progressed in severity from mild dysplasia (LSIL) to
severe lesions (HSIL) to invasive cancer. The specificity of AP-1
binding was reconfirmed in a separate band-shift assay in which
we used labeled consensus sequence of Oct-1 as a probe (Fig. 3).
While we observed absent or very low DNA binding activity in
normal and premalignant tissues, the AP-1 binding activity was
found to be highly increased in malignant tissues (Fig. 2a and b).
This trend (normal cervix  LSIL HSIL  invasive cancer) was
observed both in HPV-positive (Fig. 2a) as well as HPV-negative
(Fig. 2b) cervical tissues, showing more of a general phenomenon
irrespective of HPV infection. But there was no difference in
binding activity between control, LSIL/HSIL or cancer when
Oct-1 was used as a probe, which served as a control (Fig. 3).
Alteration in heterodimerization pattern of AP-1 is crucial for
progression to malignancy
To understand the role of the elevated binding of AP-1 tran-
scription factor, which is normally indispensable for efficient HPV
expression, AP-1 complexes were dissected to their individual
components in EMSAs using specific antibodies raised against
different members of the AP-1 family, e.g., c-jun, JunB, JunD,
c-fos, fosB, fra1 and fra2 (Fig. 4). The supershift analysis revealed
a preferential heterodimerization between c-fos and JunB instead
of its canonical dimerization partner c-jun. In all malignant tissues
analyzed, more than 80% of the supershifted band was formed by
c-fos only, while other members of the fos family (fosB, fra1, fra2)
showed no or negligible shift after incubation with the respective
antibodies. Of the jun family members, JunB was found to be the
major dimerization partner for c-fos in the majority of the samples
(n  42/50). However, c-jun and JunD were also found to show a
minor shift, in a very few samples.
Expression dynamics of the AP-1 family of proteins in cervical
tissues
Western blotting experiments were performed to analyze the
level of expression of AP-1 family of proteins during the
progression of cervical lesions. Most interestingly, c-jun was
found to uniformly exhibit a moderate level of expression from
normal controls and premalignant cases to cancer (Fig. 5). In
contrast, mainly JunB and partially JunD proteins showed dif-
ferential expression between normal, premalignant and malig-
nant samples. While a very low or negligible expression of
JunB and JunD was observed in normal and premalignant
tissues, a very high expression of junB was observed in malig-
nant tissues (see Fig. 5). Among the fos family members, c-fos
showed a gradual increase in expression as the severity of lesion
increased. While c-fos showed a very low expression in normal
samples and a moderate expression in premalignant lesions, the
severe dysplastic lesions (HSIL) and tumor tissues showed a
very strong expression. Interestingly, a completely opposite
trend was observed for Fra-1, which showed a very high ex-
pression in normal cervical tissues and it gradually decreased
with the increasing severity of the lesion and was almost absent
in invasive tumor (Fig. 5). FosB and Fra-2 showed an incon-
sistent pattern of low to moderate expression in all the types of
cervical tissues. Although there were minor differences ob-
served between samples for the expression of the AP-1 family
members, in general, they followed the severity-dependent
trend of expression. The quality and quantity of expression of
the AP-1 family members in normal, premalignant and malig-
nant cervical lesions is presented in Table I.
FIGURE 3 – EMSA carried out with labeled oligonucleotides encom-
passing a consensus sequence of Oct-1 transcription factor showing
uniform binding activity in different grades of cervical tissue extracts.
Lane a, normal controls (N); Lane b, low-grade squamous intraepithe-
lial lesions (LSIL); Lane c, high-grade squamous intraepithelial lesions
(HSIL); Lane d, invasive cancer (C). The positions of the specific
retarded bands are indicated. FIGURE 4 – Electromobility supershift analysis using nuclear ex-
tracts from invasive cervical tissues with 32P-labeled oligonucleo-
tides harboring an AP-1 consensus sequence showing differential
binding activity of AP-1 components. Tumor cell nuclear extracts
were incubated with specific antibodies (Abs) recognizing different
members of the Fos/Jun family. Lane a, without Ab; Lane b,
addition of c-Jun Ab; Lane c, addition of JunB Ab; Lane d, addition
of JunD Ab; Lane e, addition of c-Fos Ab; Lane f, FosB Ab
addition; Lane g, Fra-1 Ab addition; Lane h, Fra-2 Ab addition. The
position of the AP-1 specific complex is indicated. The arrowhead
indicates the supershifted bands after antibody addition. The
squares mark the unspecific complexes.
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Transcriptional profile of c-fos and Fra-1 during progression of
cervical lesions
The mRNA expression profile of c-fos, Fra-1 and other mem-
bers of AP-1 was analyzed in different grades of cervical lesions
including controls and cancers by Northern blot hybridization,
which revealed a complete absence of c-fos expression in normal
as well as in premalignant lesions (LSIL), but a moderate to very
high expression in severe dysplasia (HSIL) and cervical tumor
tissues, respectively (Fig. 6). In contrast, Fra-1 mRNA exhibited a
completely reversed pattern of expression; it was very high in
control and premalignant tissues, but it gradually decreased as the
severity of the lesion increased and it became nil in invasive
cancer. The other members of AP-1 exhibited a similar pattern of
expression as seen for their proteins (data not shown).
Curcumin can selectively suppress HPV18 transcription in HeLa
cells
In a pilot experiment, which was repeated at least 3 times, we
incubated the HPV 18-positive cervical carcinoma cells, HeLa, in
different concentrations of curcumin (50 M, 100 M and 200
M) for a fixed duration of 1 hr as well as for different time
periods (15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 12 hr and
24 hr). The results revealed a time- and concentration-dependent
decrease in HPV18 expression (Fig. 7). After having analyzed
these results, an optimum effective treatment time of 1 hr and a
nontoxic dose of 100 M; curcumin was finalized for further
experiments. The cell viability after the curcumin treatment in this
concentration was verified by MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay,31 which showed no cell
death, indicating nontoxicity of the dose. Incubation of HeLa cells
with 100 M curcumin for different periods showed that by 2.5 hr
of incubation, a slight decline in HPV18-specific mRNA expres-
sion was observed and by 4–5 hr the HPV18 expression was
completely abolished (Fig. 7). This abolition of HPV transcription
was found to be selective and virus-specific and not the conse-
quence of a general transcriptional blockage, since curcumin has
no effect on the expression of the endogenous control gene -actin
(Fig. 7). Since the disappearance of HPV18 mRNA follows
roughly the same kinetics as observed for HPV16, with the half-
life of its mRNA being 2.5 hr,7 curcumin interference seems to act
at the level of initiation of transcription. This is also due to our
findings that the disappearance of viral mRNA follows similar
kinetics (approximately 2.5 hr) as observed after treatment of
HeLa cells with a nonspecific transcription inhibitor, actinomycin
D (Fig. 8). The viral mRNA, however, started reappearing by 8–9
hr and regained its normal expression by 12 hr (data not shown)
possibly because of complete metabolization of the drug.
Curcumin downregulates the AP-1, but not the SP-1,
transcription factor
Incubation of HeLa cells with 100 M curcumin for different
durations indicated time-dependent downregulation of AP-1 bind-
ing activity. The AP-1 binding activity started declining after about
2 hr, by which time HPV18 transcription also showed a decline,
and became completely abolished by 4–5 hr (Fig. 9). To investi-
gate the specificity of the effect of curcumin on AP-1, we analyzed
its effect on other transcription factors such as SP-1. But we could
not find any inhibitory effect of curcumin on the SP-1 transcription
factor (data not shown).
Curcumin downregulates c-fos, but upregulates fra-1, expression
Most interestingly, when we analyzed the protein expression
pattern of c-fos following 100 M curcumin treatment for differ-
ent durations (15 min, 30 min, 1 hr, 2 hr, 3 hr and 5 hr), it first
showed a decrease in c-fos expression by 2 hr and further de-
creased gradually in the following hours until it was completely
abolished by 4–5 hr. In contrast, fra-1, which was almost nil in
untreated HeLa cells, showed its clear appearance by the same
time period of 2 hr (when c-fos had started declining) and by 4–5
hr, the fra-1 expression reached its peak (Fig 10). It is very
interesting to note that even though the c-fos mRNA level became
almost nil after about 2 hr of curcumin treatment (Fig. 7), the c-fos
protein remains there up to about 3–4 hr. This may be because the
preexisting c-fos protein pool remains for a few hours and is then
gradually metabolized, although the transcriptional machinery is
blocked by 2 hr of curcumin treatment. Additional experiments
were also carried out to detect variation in other AP-1 components
after curcumin treatment but no major change in AP-1 composition
could be discerned. We also checked the change in composition of
the AP-1 binding activity after 100 M curcumin treatment. Since
AP-1 binding activity starts decreasing by 2 hr and becomes nil
after around 4–5 hr, we could analyze the AP-1 composition only
at 1 hr of curcumin treatment. We found that JunB remains the
major component, but involvement of c-fos becomes almost nil
(Fig. 11). A very small amount of Fra1 and Fra2 reappears, but the
rest of the components showed no change in their involvement.
Curcumin also downregulates p53-responsive gene WAF-1/p21
It has been shown that HPV transcription can be downregulated
by p53 and is mediated through the epithelial cell-specific en-
hancer element within the viral URR.32 In contrast, our previous
study had shown that a synthetic antioxidant, PDTC, however,
does not affect p53 expression. To reanalyze this, we examined the
expression level of the WAF-1/p21 gene, representing a known
downstream target for altered p53 activity.28 Thinking that p53
FIGURE 5 – Differential expression pattern of different members of
the AP-1 family of proteins in normal, dysplasia (LSIL and HSIL) and
cancerous lesions of the uterine cervix. A total of 30 g protein each
from control, dysplasia and cancer cases was separated in a 10%
SDS-PAGE minigel. After electrotransfer, the filters were consecu-
tively incubated with different antibodies of AP-1 family (c-fos, Fra-1,
c-jun, JunB, JunD, Fra2 and fosB). To confirm equal protein loading,
the filters were reincubated with a monoclonal -actin antibody. Lanes
a and b, normal controls; Lane c, low-grade squamous intraepithelial
lesions (LSIL); Lane d, high-grade squamous intraepithelial lesions
(HSIL); Lanes e and f, invasive cancers. Note that there is a high
expression of c-Fos in cancer tissues, while Fra-1 is completely absent.
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activation is not directly involved in viral gene suppression, we
expected to see no change in WAF-1/p21 expression. But to our
surprise, we found that as the HPV18 expression gradually de-
creased, the expression of the cyclin-dependent kinase inhibitor
WAF-1/p21 also decreased and became nil after 2 hr of curcumin
treatment (Fig. 7). These results indicate that p53 may play a role
in HPV downregulation, since unlike PDTC, which has no effect
on p53 expression, curcumin downregulates p53 expression.
Whether the lack of p53 expression has some later effects needs to
be clarified in further experiments.
Discussion
The 2 transforming early genes E6 and E7 of high risk HPV16
and HPV18, possess an intrinsic transactivation capacity on their
own homologous promoters,33,34 but constitutive expression of E6
and E7 in immortalized or malignantly transformed human kera-
tinocytes is mainly dependent on the availability of a defined set of
transcription factors, such as AP-1, derived from the infected host
cells. Our results show that the AP-1 binding activity is very high
in cervical tumor tissues, whereas it is nil or negligible in normal
cervical cells. This strengthens the previous hypothesis that the
activator protein, AP-1, is not only the major determinant for tissue
specificity,8 but is also absolutely indispensable for efficient HPV
oncogene expression.7 The high binding activity of AP-1 is also
observed in several other tumors,35–39 including cervical tumors
that do not contain HPV infection, so its direct relation to HPV is
still not very clear.
Assuming that an alteration in the composition of AP-1 either
directly or indirectly regulates the transactivation and DNA bind-
ing activity, which in turn pushes the normal cells into a prema-
lignant or malignant state, we analyzed the AP-1 binding activity
in normal as well as different grades of cervical carcinoma tissues.
The most interesting observation was an increased c-fos expres-
sion and a decreased Fra-1 expression with the increasing severity
of cervical lesions during progression (Fig. 6). A very high ex-
pression of c-fos protein was found in malignant cervical tissues,
supporting the results of EMSA, which also indicates that the
major dimerization partner of active AP-1 complex is c-fos. c-fos
as a part of transcription factor AP-1 is known to play a central role
in signal transduction by coupling short-term stimulation of the
cell to long-term alterations in gene expression.40 Evidence has
also indicated that c-fos alone is capable of transforming the cells
in vitro.41 A previous study42 using nontumorigenic HeLa fibro-
blast hybrids “444” cells, their tumorigenic segregates “CGL3”
and HPV18-positive HeLa cells, showed that c-fos is highly ex-
pressed in tumorigenic HeLa and CGL3 cells but completely
absent from AP-1 complexes in nontumorigenic 444 cells. Con-
versely, fra-1 concentration is low or nil in extracts from tumori-
genic cells (HeLa and CGL3) and very high in nontumorigenic 444
TABLE I – QUALITY AND QUANTITY OF EXPRESSION OF THE AP-1 PROTEINS IN NORMAL, PREMALIGNANT AND
MALIGNANT LESIONS OF THE UTERINE CERVIX OF WOMEN1
Protein
Normal (n  30) Premalignant (n  50) Malignant (n  50)
Nil Weak Medium Strong Nil Weak Medium Strong Nil Weak Medium Strong
c-Jun – 8 22 – – 4 44 2 1 9 38 2
JunB 28 2 – – 42 8 – – – 2 10 38
JunD 30 – – – 37 13 – – – 4 20 26
c-fos 5 22 3 – 3 30 17 – – – 4 46
FosB 0 5 10 15 0 10 20 20 0 28 10 12
Fra-1 1 1 6 22 – 2 18 30 46 4 – –
Fra-2 0 2 10 18 23 7 18 2 6 20 20 4
1Arbitrary level of expression: strong  ; medium  ; weak  ; nil  –.
FIGURE 6 – Northern blot analysis showing mRNA expression pro-
file of c-fos, Fra-1 and -actin genes in normal as well as different
grades of cervical lesions including cancer. Lane a, normal controls
(N); Lane b, low-grade squamous intraepithelial lesions (LSIL); Lane
c, high-grade squamous intraepithelial lesions (HSIL); Lane d, inva-
sive cancer (C). To confirm equal RNA loading, the filters were
reincubated with -actin probes.
FIGURE 7 – Time-dependent downregulation of HPV 18 transcrip-
tion in presence of curcumin. Northern blot analysis showing selective
downregulation of HPV-18, c-fos and WAF-1 mRNA expression in
HeLa cells and upregulation of Fra-1 mRNA expression after 100 M
curcumin treatment at different time intervals. Lane a, untreated cells;
Lanes b–h, 15 min, 30 min, 1 hr, 2 hr, 3 hr, 5 hr and 6 hr of incubation
in the presence of 100 M curcumin, respectively. To confirm equal
RNA loading, the filters were reincubated with -actin probes. The
positions of the 28S and 18S rRNAs are indicated.
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cells.42 Furthermore, ectopic expression of c-fos and reconstitution
of sufficient amount of c-fos in 444 cells induced tumorigenicity
where fra-1 expression was completely abolished in favor of c-fos,
which showed very high expression.42 We now demonstrate for the
first time similar results in in vivo tissues from women with
precancerous and cancerous lesions and controls and we suggest
that c-fos plays a crucial role in the process of tumorigenic trans-
formation of cervical epithelium.
Most interestingly, in a perfect reverse correlation with the
upregulated c-fos expression, the fos-related antigen, fra-1, re-
vealed a gradual downregulation with the increasing disease se-
verity and became almost nil in invasive cancer. Similar expres-
sion dynamics of c-fos and fra-1 have also been observed in other
cancer tissues in vivo (Prusty and Das, unpublished results). This
is in sharp contrast to what has been reported by other authors in
other epithelial cancers.35–39 The possible explanation for this
could be that they have observed overexpression of Fra-1 in
carcinoma cell lines, while our findings are mainly in in vivo tumor
tissue specimens. Our results indicate that fra-1 must have tumor
suppressor functions. This is further strengthened by the fact that
the fra-1 gene is located in the region of chromosome 11q13,43
which is known to harbor a tumor suppressor gene and is often
structurally deleted or rearranged in cervical cancer cells.44 It has
also been shown that enhanced fra-1 expression can abolish trans-
activation of c-jun/c-fos complexes on AP-1–responsive genes.45
Although the overexpression of fra-1 alone has so far failed to
cause significant suppression of HPV expression, it has recently
been shown to inhibit cell proliferation, induce apoptosis and
reduce tumorigenicity of C6 glioma cells.46 Nevertheless, the
contrasting expression dynamics of c-fos and fra-1 appear to play
a crucial role during the process of tumorigenic progression of
cervical lesions, in which fra-1 appears to play a negative regula-
tory role during the multistep process of cervical carcinogenesis.
Several different Jun family members, mainly JunB, partici-
pated in the increased AP-1 DNA binding activity and were
overexpressed in carcinomas. In HeLa cells a 3-fold increase in
junB expression has been reported.47 Interestingly, although c-Jun
was consistently expressed in normal, premalignant and malignant
tissues in vivo in good amount, it was not found to be involved in
the dimerization and DNA binding activity, as evidenced in su-
pershift assays (Fig. 4). This confirms that junB constitutes the
major dimerization partner of c-fos within the AP-1 complex that
participates in tissue-specific transcriptional activation and HPV
oncogene expression.7,48 Studies indicate that c-Jun and JunB
function as immediate growth factor response genes and that
activation of these 2 genes is required for cell-cycle progression.49
But c-Jun and junB also have antagonistic functions during onco-
genic transformation and cell proliferation.50,51 It has been shown
that junB can largely substitute for c-jun in vivo52 and can inhibit
the transforming activities of c-jun.53 Deregulated junB expression
can rescue the jun target genes that are regulated by jun/fos–based
sequences. This indicates that the antagonistic effect of junB on
jun-mediated transcription is dependent on the physical presence
of jun, and supports the previous concept of a transcriptionally
FIGURE 8 – Determination of the half-life of HPV-18 RNA. HeLa
cells were treated with 10 g of actinomycin-D per milliliter and RNA
was extracted 15 min, 30 min, 1 hr, 2 hr, 3 hr and 5hr after the addition
of the drug. Lane a, untreated cells (UT); Lanes b–g, 15 min, 30 min,
1 hr, 2 hr, 3 hr and 5 hr of incubation in the presence of 100 M
curcumin, respectively. To confirm equal amount of RNA loading, the
filters were reincubated with -actin probes. The positions of the 28S
and 18S rRNAs are indicated.
FIGURE 9 – EMSA showing time-dependent downregulation of
AP-1 binding activity in HPV-18 positive HeLa cell extracts following
the treatment of cells with curcumin for different periods. Lane a,
untreated cells; Lanes b–g, 15 min, 30 min, 1 hr, 2 hr, 3 hr and 5 hr
of incubation in the presence of 100 M curcumin, respectively. The
positions of the specific retarded bands are indicated. Note that the
binding activity of AP-1 diminishes by 2 hr and it completely disap-
pears by 4–5 hr.
FIGURE 10 – Time-dependent downregulation of c-fos protein ex-
pression and upregulation of Fra-1 expression in presence of 100 M
curcumin. HPV-18 positive HeLa cells were treated with 100 M
curcumin for different periods and protein was extracted at each
time-point. Separation of 30 g protein was done in a 10% SDS-
PAGE gel. After electrotransfer, the filters were consecutively incu-
bated with c-Fos and Fra-1 antibodies. Lane a, untreated cells; Lanes
b–g, 15 min, 30 min, 1 hr, 2 hr, 3 hr and 5 hr of incubation in the
presence of 100 M curcumin, respectively. To confirm equal protein
loading, the filters were reincubated with a monoclonal -actin anti-
body.
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inactive jun/junB dimer.53 It can be speculated that in addition to
a simple competition with JunB to bind with c-fos, posttransla-
tional modifications of c-Jun may account for the exclusion of
c-Jun from AP-1 complex formation.
The AP-1 is also a direct target for the E7 oncogene, which
posttranslationally interacts with c-Jun in elevating its transactiva-
tion activity.54 In the absence of c-jun in the AP-1 binding com-
plex, higher junB levels are probably required to restore similar
AP-1 binding activity and to ensure similar AP-1–mediated tran-
scriptional activation. A low involvement of JunD in some cases
may appear to be paradoxical, since this protein has usually been
assigned an antagonistic role in oncogenic transformation. How-
ever, recent evidence suggests that this might be an oversimplified
explanation, because JunD–/– embryonic fibroblasts display a re-
tarded growth55 and menin, a tumor suppressor gene, when asso-
ciated with JunD inhibits its transactivation.56 Although FosB
shows inconsistent expression in malignant cervical tissues, its role
is still unclear.
The most interesting finding of our study is the selective down-
regulation of HPV18 transcription in HeLa cells following cur-
cumin treatment. This is the first time it has been demonstrated that
expression of HPV can be specifically suppressed by an antioxi-
dant of herbal origin. It follows almost the same kinetics as
revealed by treatment with a transcription inhibitor actinomycin D;
therefore it is clear that curcumin acts at the level of initiation of
transcription, since downregulation of HPV transcription begins by
2.5 hr, which is also estimated to be approximately the half-life of
the HPV18-specific mRNA (Figs. 7 and 8).
The observation that curcumin-induced suppression of HPV18
expression is paralleled by concomitant abolition of AP-1 binding
to the viral upstream regulatory region (URR) is indicative of the
fact that AP-1 is indispensable for efficient viral gene expression.
This is in sharp contrast to our earlier observation with a synthetic
antioxidant, PDTC, which did suppress HPV expression but in-
creased the binding activity of the AP-1 complex. This has been
shown to be caused either by changing the composition of AP-1
and/or by posttranslational modifications.7 But curcumin appears
to follow a different pathway; it does not depend much on the
alteration in AP-1 composition, but it acts at the transcriptional
level and downregulates the expression of its components. Al-
though the therapeutic potential of curcumin is implicit, the mech-
anism(s) of curcumin-induced inhibition of AP-1 binding is not yet
clearly understood. It is known that DNA binding of the Jun/Fos
complex could be modulated by redox regulation of a single
conserved cysteine residue located in the DNA binding domain.57
But it is also possible that curcumin may work in other ways than
just as an antioxidant that brings about changes in the redox status
of the cell. Whether there exists a curcumin responsive receptor/
element or whether curcumin can activate/inhibit some cellular
protein(s) or protein kinases that in turn can interact with Jun/Fos
binding, is not known. It is possible that curcumin can act through
inhibition of JNK, a c-Jun N-terminal kinase needed for AP-1
activation.58 Another possibility could be that curcumin may di-
rectly inhibit formation of the jun-fos DNA complex.59
To gain further insight into the effects of curcumin, we per-
formed Northern as well as immunoblot analysis, which revealed
a time-dependent downregulation of c-fos expression matching the
downregulation of AP-1 activity; but most interestingly, curcumin
upregulated fra-1 expression to a level generally observed in
normal cervical cells (Fig. 5). This further strengthens the possible
role of fra-1 in tumor suppression. Thus the inverse correlation of
expression dynamics between c-fos and fra-1, along with the
changed heterodimerization pattern between c-fos and jun-B
within the AP-1 complex, appears to play a crucial role during
development and tumorigenic progression of cervical cancer.
Since p53 is redox-regulated through specific cysteine residues
within the DNA binding domain60 and p53 overexpression alone is
sufficient to downregulate HPV16/HPV18 transcription through
the epithelial cell–specific enhancer element within the viral
URR61 and since p53-inactivating interaction with HPV16/HPV18
E6 oncoprotein is not an irreversible process, we looked for
expression of cyclin-dependent kinase inhibitor WAF-1/p21,
which is a known downstream target gene for p53. Interestingly,
unlike our previous results with PDTC,7 which does not affect the
steady-state level of p53, or WAF-1, we found downregulation of
the p53 target gene WAF-1 expression, instead of its expected
upregulation, indicating a possible role of p53 in downregulating
HPV transcription. It remains to be elucidated as to how and by
what mechanism(s) the expression of WAF-1 is downregulated.
Since AP-1 is an indispensable key regulator of epithelial cell–
specific transcriptional activity of various HPV types,7,9,62,63 cur-
cumin-induced abolition of AP-1 binding activity (in which its major
binding partner c-fos disappears but fra-1 reappears at a level similar
to that in normal controls) is sufficient for selective suppression of
HPV oncogene expression. Since curcumin has been shown to have
very low or no pharmacological toxicity, our study provides a basis
for using potent antioxidative agents such as curcumin for developing
novel chemotherapeutic approaches to impair the expression of patho-
genic HPVs for control of cervical cancer.
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FIGURE 11 – HeLa cells were grown in the presence of 100 M
curcumin for 1 hr. Band supershift assay was done using 32P-labeled
oligonucleotides harboring the AP-1 consensus sequence. HeLa cell
nuclear extracts were incubated with specific Abs recognizing differ-
ent members of the Fos/Jun family. Lane a, without Ab; Lane b,
addition of c-Jun Ab; Lane c, addition of JunB Ab; Lane d, addition of
JunD Ab; Lane e, addition of c-Fos Ab; Lane f, FosB Ab addition;
Lane g, Fra-1 Ab addition; Lane h, Fra-2 Ab addition. The position of
the AP-1 specific complex is indicated. The arrowhead indicates the
supershifted bands after Ab addition.
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